Diligence memo · auto-generated · as of July 2, 2026

ProstaGene, LLC

ProstaGene, LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

ProstaGene, LLC operates in Pharmaceuticals, based in PHILADELPHIA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ProstaGene, LLC has raised $1.6M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $825K on 2015-02-23.

Most recent recorded round closed around 2016-04-08.

Valuation (modeled)modeled

Provath models ProstaGene, LLC at approximately $19M (range $224K–$215M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.00× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 10.2 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.1× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 25% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 27% of those peers.

Closest niche peers: Essentia Pharma Socal, Llc, Essentia Pharma Florida, Llc, Novellus LLC, Blake Insomnia Therapeutics, Inc., Eleusis Benefit Corporation, PBC.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.